Eli Lilly (LLY) weight loss pill orforglipron gets US FDA approval

Eli Lilly's recent FDA approval of its weight loss pill orforglipron is a significant positive catalyst for the stock and the broader pharmaceuticals sector.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

European Closes: Euro Stoxx 50 +3.05% at 5,740, Dax 40 +3.01% at 23,314, FTSE 100 +1.84% at 10,364, CAC 40 +2.10% at 7,981, FTSE MIB +3.22% at 45,736, IBEX 35 +3.15% at 17,586, PSI +1.84% at 9,300, SMI +1.44% at 13,006, AEX +1.76% at 977

US military officials are planning for two potential ground assaults in Iran: one on Kharg Island, the hub of the country’s energy industry, and the other to seize enriched uranium, Atlantic reports, citing source

Eli Lilly (LLY) weight loss pill orforglipron gets US FDA approval

Iran's Deputy Info Officer of President Office says stance on war unchanged, continues to defend nation, Tasnim reports

Ukrainian President Zelensky holding talks with US negotiators, according to reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This approval not only validates Eli Lilly's R&D efforts but could also enhance its revenue outlook in the competitive weight loss market, potentially influencing investor sentiment and stock performance in the health and biotech sectors.

Related headlines

The whole workspace, free to try.

Try it free